Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Outlines Priority Actions For Tackling AMR In 2024

Executive Summary

An updated priority pathogen list, a review of the clinical pipeline for antibacterials, and high-level meetings with other global regulators are among the steps that will be taken by the World Health Organization in the year ahead to combat antimicrobial resistance.

You may also be interested in...



WHO Tightens Up Guidance On Reserving Most Critical Antimicrobials For Humans Only

All new classes of antimicrobials for human use will fall within the World Health Organization’s highest criticality category under its latest guidance on preventing antimicrobial resistance.

AMR: UK’s Subscription Scheme ‘One Way Forward,’ But New Economic Models Needed

Stimulating the development of novel antibiotic drugs and diagnostics will require new funding models as part of the broader “push and pull” incentives strategy, says the director of health & life sciences at Innovate UK.

WHO Publishes List Of Pathogen Threats To Rouse Drug Developers

The World Health Organisation has released a list of 12 bacteria it says pose the greatest threat to human health as a way of urging governments and the drug development industry to incentivize and launch an R&D response against the increasing global issue of antibiotic resistance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel